Heart Failure Seminar: Updates in Advanced Heart Failure, LVAD Is In Place, Now What? Current Thoughts on Antithrombetic Therapy-HF Seminar

Video Transcription

Video Summary

In a webinar by Dr. Jacob Schroeder and Dr. Pollack Shaw at the Heart Failure Society of America, advanced heart failure updates, heart transplant techniques, and organ preservation were discussed. Dr. Schroeder highlighted the importance of optimizing advanced heart failure therapies and advancements in organ preservation. Dr. Shaw focused on LVAD patient management, discussing medical therapy, reverse remodeling, and antithrombotic therapy updates. The ARES trial findings were shared, suggesting aspirin exclusion in HeartMate 3 LVAD patients and exploring apixaban as an alternative to warfarin. Emphasizing close monitoring and new approaches, they aimed to improve outcomes. They discussed challenges in managing LVAD patients, including anticoagulation choices, RV failure management post-LVAD, and the initiation timing of guideline-directed medical therapy (GDMT). Transitioning from warfarin to apixaban was suggested cautiously pending more data. RV mechanical support, preload, afterload optimization, and the cautious introduction of certain medications post-LVAD were also highlighted. Furthermore, ethical considerations regarding donation after circulatory death and organ procurement methods like NRP were discussed, impacting organ availability.

Keywords

webinar

Dr. Jacob Schroeder

Dr. Pollack Shaw

Heart Failure Society of America

advanced heart failure updates

heart transplant techniques

organ preservation

LVAD patient management

ARES trial findings

HeartMate 3 LVAD patients

anticoagulation choices

organ procurement methods